CSIMarket


Syros Pharmaceuticals Inc   (SYRS)
Other Ticker:  
 


 

Syros Pharmaceuticals Inc

SYRS's Financial Statements and Analysis



Syros Pharmaceuticals Inc narrowed third quarter of 2023 net loss per share of $-1.43 compare to net loss per share of $-3.21 recorded in the same quarter a year ago a decrease compare to $-1.30 realized in previous quarter.


third quarter of 2023
Earnings Per Share Revenues
$ -1.43 $  4 Mill
$+1.78     Unch.     -3.32 %



Syros Pharmaceuticals Inc 's Revenue fell by -3.32 % in third quarter of 2023 (Sep 30 2023) year on year, to $4 million and advanced by 32.79 % sequentially.


Syros Pharmaceuticals Inc is

More on SYRS's Income Statement



Syros Pharmaceuticals Inc in the third quarter of 2023 recorded net loss of $-40.143 million, an increase from net loss of $-30.253 million in III. Quarter a year ago.

Sequentially net loss advanced

More on SYRS's Growth

Syros Pharmaceuticals Inc Inventories
In Sep 30 2023 company's net cash and cash equivalents decreased by $-3 million


Syros Pharmaceuticals Inc does not pay out common stock dividend.

In trailing twelve-month period Syros Pharmaceuticals Inc payed $ -4.37 cash per share, on a free-cash flow basis .

Book value fell by -50.57 % sequentially to $1.30 per share, -33.52% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 1.30 per share from $ 2.62.

Company issued 0.08 million shares or 0.28 % in Sep 30 2023.


More on SYRS's Dividends

 Market Capitalization (Millions) 139
 Shares Outstanding (Millions) 28
 Total Debt (Millions $) 41
 Revenue (TTM) (Millions $) 9
 Net Income (TTM) (Millions $) -105
 Cash Flow (TTM) (Millions $) -59
 Capital Exp. (TTM) (Millions $) -1
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Syros Pharmaceuticals Inc does not pay out common stock dividend.

In trailing twelve-month period Syros Pharmaceuticals Inc had negative $ -4.37 cash flow per share, on a free-cash flow basis .

Book value fell by -50.57 % sequentially to $1.30 per share, -33.52% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 1.30 per share from $ 2.62.

Company issued 0.08 million shares or 0.28 % in Sep 30 2023.


More on SYRS's Balance Sheets

 Market Capitalization (Millions) 139
 Shares Outstanding (Millions) 28
 Total Debt (Millions $) 41
 Revenue (TTM) (Millions $) 9
 Net Income (TTM) (Millions $) -105
 Cash Flow (TTM) (Millions $) -59
 Capital Exp. (TTM) (Millions $) -1
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Syros Pharmaceuticals Inc Earnings

Hematologic Malignancy Revolution: Syros Pharmaceuticals Inc Faces Unique Challenges and Opportunities Amidst -3.315% Revenue Slide



Syros Pharmaceuticals Inc, a biopharmaceutical company focused on revolutionizing hematologic malignancy treatments, recently released its financial results for the most recent fiscal period. With both positive and negative indicators, the company faces unique challenges and opportunities. This article will examine the implications of the financial results on Syros Pharmaceuticals Inc and its potential trajectory moving forward.
Improving Losses, but Room for Growth:
In the most recent fiscal period, Syros Pharmaceuticals Inc showcased progress in controlling losses. The company's loss per share decreased from $-3.21 to $-1.43 compared to the previous year. Furthermore, the loss per share r...

Syros Pharmaceuticals Inc Faces Challenging Quarter with Plummeting Revenue and Share Shortfall



Syros Pharmaceuticals Inc, a major player in the pharmaceutical preparations industry, has recently disclosed its financial results for the period of April to June 30, 2023. The company experienced a disastrous quarter, marked by a significant decline in revenue and an expansion of the shortfall per share. This article aims to outline the facts from the financial results and put them into context by examining recent developments in the company's share performance.
Financial Results:
Syros Pharmaceuticals Inc reported a steep decline in revenue for the April to June 30, 2023 period. Revenue decreased by a staggering -54.86% to $2.83 million compared to the same reporting season in the previo...

Syros Pharmaceuticals Inc Faces Steep Decline in First Quarter of 2023, Resulting in Crumbling Revenue

Syros Pharmaceuticals Inc has been experiencing a concerning trend of losses and negative returns on equity over the past 12 months. During this period, the company recorded a cumulative net loss of $-93 million, resulting in a negative return on equity of -94.55%. This poor performance is particularly alarming given that within the Major Pharmaceutical Preparations industry, 162 other companies had a higher return on equity.
Despite a slight improvement in overall ranking from 3961 in the fourth quarter of 2022 to 2445 currently, the company's financials for the first quarter of 2023 paint a bleak picture. Notably, Syros Pharmaceu...


Date modified: 2023-11-16T19:22:29+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com